Cargando…
PD-1 Cellular Nanovesicles Carrying Gemcitabine to Inhibit the Proliferation of Triple Negative Breast Cancer Cell
PD-1 inhibitor Keytruda combined with chemotherapy for Triple-negative breast cancer (TNBC) has been approved for FDA, successfully representing the combination therapy of immunotherapy and chemotherapy for the first time in 2020. However, PD-L1 inhibitor Tecentriq combined with albumin paclitaxel u...
Autores principales: | Zha, Hualian, Xu, Zhanxue, Xu, Xichao, Lu, Xingyu, Shi, Peilin, Xiao, Youmei, Tsai, Hsiang-I, Su, Dandan, Cheng, Fang, Cheng, Xiaoli, Chen, Hongbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229990/ https://www.ncbi.nlm.nih.gov/pubmed/35745835 http://dx.doi.org/10.3390/pharmaceutics14061263 |
Ejemplares similares
-
Fe(3+)-binding transferrin nanovesicles encapsulating sorafenib induce ferroptosis in hepatocellular carcinoma
por: Xiao, Youmei, et al.
Publicado: (2023) -
Plant exosomes fused with engineered mesenchymal stem cell‐derived nanovesicles for synergistic therapy of autoimmune skin disorders
por: Huang, Rufan, et al.
Publicado: (2023) -
Exosomal PD-L1 functions as an immunosuppressant to promote wound healing
por: Su, Dandan, et al.
Publicado: (2019) -
Protocol to prepare functional cellular nanovesicles with PD1 and TRAIL to boost antitumor response
por: Yu, Peiwen, et al.
Publicado: (2021) -
Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy
por: Chen, Hu, et al.
Publicado: (2022)